275 related articles for article (PubMed ID: 34454469)
1. Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
Hackshaw MD; Danysh HE; Henderson M; Wang E; Tu N; Islam Z; Ladner A; Ritchey ME; Salas M
BMC Cancer; 2021 Aug; 21(1):967. PubMed ID: 34454469
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
[TBL] [Abstract][Full Text] [Related]
3. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.
Park IH; Ro J; Lee KS; Nam BH; Kwon Y; Shin KH
Ann Oncol; 2009 Jan; 20(1):56-62. PubMed ID: 18664558
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy.
Tsuruoka S; Kataoka M; Uwatsu K; Makita K; Tsuruoka K; Takata N; Ishikawa H; Hamamoto Y; Mochizuki T; Kido T
Asia Pac J Clin Oncol; 2023 Jun; 19(3):347-354. PubMed ID: 36281655
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
10. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.
Melisko ME; Moore DH; Sneed PK; De Franco J; Rugo HS
J Neurooncol; 2008 Jul; 88(3):359-65. PubMed ID: 18398574
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
12. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab.
Kaplan MA; Ertugrul H; Firat U; Kucukoner M; İnal A; Urakci Z; Pekkolay Z; Isikdogan A
Breast Cancer; 2015 Sep; 22(5):503-9. PubMed ID: 24385387
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer subtypes and survival in patients with brain metastases.
Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
[TBL] [Abstract][Full Text] [Related]
17. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
Eichler AF; Kuter I; Ryan P; Schapira L; Younger J; Henson JW
Cancer; 2008 Jun; 112(11):2359-67. PubMed ID: 18361426
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
[TBL] [Abstract][Full Text] [Related]
19. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
[TBL] [Abstract][Full Text] [Related]
20. HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases.
Michel A; Oppong MD; Rauschenbach L; Pierscianek D; Dinger TF; Schmidt T; Hense J; Pöttgen C; Kimmig R; Ahmadipour Y; Özkan N; Müller O; Junker A; Sure U; Jabbarli R; El Hindy N
World Neurosurg; 2021 Aug; 152():e332-e343. PubMed ID: 34062302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]